Prostate-specific antigen prostate cancer screening: Answers to the critical questions

Annals of Long-Term Care

Volumn 20, Issue 10, 2012, Pages 16-21

  Austin, Orson J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer screening; ERSPC trial; Informed decision making; PLCO trial; Prostate cancer; Prostate cancer mortality; Prostate specific antigen testing; Shared decision making

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COMORBIDITY; DECISION MAKING; DIAGNOSTIC ACCURACY; HIGH RISK POPULATION; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

EID: 84872971906     PISSN: 15247929     EISSN: 19435010     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Wolf AM, Wender RC, Etzioni RB, et al; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. Ca Cancer J Clin. 2010;60(2):70-98.
3. Warshaw G. Providing quality primary care to older adults. J Am Board Fam Med. 2009;22(3):239-241.
4. Hudson SV, Ohman-Strickland P, Ferrante JM, Lu-Yao G, Orzano AJ, Crabtree BF. Prostate-specific antigen testing among the elderly in community-based family medicine practices. J Am Board Fam Med. 2009;22(3):257-265.
5. Andriole GL, Crawford ED, Grubb RL, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-1319.
6. Andriole GL, Crawford ED, Grubb RL 3rd, et al; PLCO Project Team. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125-132.
7. Schroder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
8. Schroder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Prostatecancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981-990.
9. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182(5):2232-2241.
10. Lin K, Lipsitz R, Miller T, Janakiraman S; US Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(3):192-199.
11. Hoffman RM. Clinical practice. Screening for prostate cancer. N Engl J Med. 2011;365(21):2013-2019.
12. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008;9(5):445-452.
13. Albertsen PC. The prostate cancer conundrum. J Natl Cancer Inst. 2003;95(13): 930-931.
14. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(11):762-771.
15. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
16. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev. 2006;(3):CD004720.
17. Hitzeman N, Molina M. Screening for prostate cancer: prostate-specific antigen testing is not effective. Am Fam Physician. 2011;83(7):802-804.
18. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ. 2011;342:d1539.
19. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543.
20. Barry MJ. Screening for prostate cancer-the controversy that refuses to die. N Engl J Med. 2009;360(13):1351-1354.
21. Eckersberger E, Finkelstein J, Sadri H, et al. Screening for prostate cancer: a review of the ERSPC and PLCO trials. Rev Urol. 2009;11(3):127-133.
22. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17): 2095-2101.
23. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302(11):1202-1209.
24. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer [published correction appears in Ann Intern Med. 2008;148(11) 888
25. Ann Intern Med. 2008;148(6):435-448
26. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117-1123.
27. Hoffman RM. Screening for prostate cancer. N Engl J Med. 2011;365(21): 2013-2019.
28. Bunker CH, Patrick AL, Konety BR, et al. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago prostate cancer survey. Cancer Epidemiol Biomarkers Prev. 2002;11(8):726-729.
29. Centers for Disease Control and Prevention. New cases of prostate cancer by race and ethnicity. www.cdc.gov/features/dsprostatecancer/index.html. Last updated August 31, 2011. Accessed October 1, 2012.
30. The VA/NCI/AHRQ Cooperative Studies Program #407: Prostate Cancer Intervention Versus Observation Trial (PIVOT): main results from a randomized trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. Presented at the 107th Annual Meeting of the American Urological Association; May 14-19, 2011; Washington, DC.
31. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. http://seer.cancer. gov/csr/1975-2008/index.html. Accessed October 1, 2012.
32. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859-864.
33. Spalding MC, Sebesta SC. Geriatric screening and preventive care. Am Fam Physician. 2008;78(2):206-215.
34. ePrognosis calculator. Estimating progosis for elders. www.eprognosis.org/p/ calculators.html. Accessed October 1, 2012.
35. Life expectancy calculators. www.lifeexpectancycalculators.com. Accessed October 1, 2012.
36. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296(19):2336-2342.
37. Bangma CH, Roemeling S, Schroder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol. 2007;25(1):3-9.
38. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-990.
39. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate- specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.
40. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19):1325-1329.
41. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate- specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.
42. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-990.
43. Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012;344:d7894.
44. Ganz PA, Barry JM, Burke W, et al. National Institutes of Health State-of-the- Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med. 2012;156(8):591-595.
45. Rimer BK, Briss PA, Zeller PK, Chan EC, Woolf SH. Informed decision making: what is its role in cancer screening? Cancer. 2004;101(suppl 5):1214-1228.
46. Braddock CH, Edwards KA, Hasenberg NM, Laidley TL, Levinson W. Informed decision making in outpatient practice: time to get back to basics. JAMA. 1999;282(24):2313-2320.
47. Allen JD, Othus MK, Hart A Jr, Mohllajee AP, Li Y, Bowen D. Do men make informed decisions about prostate cancer screening? Baseline results from the take the wheel trial. Med Decis Making. 2011;31(1):108-120.
48. Joseph-Williams N, Evans R, Edwards A, et al. Supporting informed decision making online in 20 minutes: an observational web-log study of a PSA test decision aid. J Med Internet Res. 2010;12(2):e15.
49. Austin OJ, Valente S, Hasse LA, Kues JR. Determinants of prostate cancer screening by primary care physicians. Arch Fam Med. 1997;6(5):453-458.
50. Friedrich MJ. Debate continues on use of PSA testing for early detection of prostate cancer. JAMA. 2011;305(22):2273-2275.
51. Miller AB. New data on prostate-cancer mortality after PSA screening. N Engl J Med. 2012;366(1):1047-1048.
52. Brownlee S, Lenzer J. Can cancer ever be ignored? The New York Times Magazine. October 9, 2011:MM40.
53. Parker-Pope T. The side effects? Well, there is one. New York Times. September 24, 2011:SR5.